- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Japan
Total 40 results
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Osaka Medical CollegeTerminatedBreast Cancer | HER-2 Positive Breast Cancer | Estrogen Receptor Negative NeoplasmJapan
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
National Cancer Center, JapanH.U. Group Research Institute G.K.RecruitingHER2-positive Breast CancerJapan
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
AstraZenecaActive, not recruitingHormone Receptor Positive Breast CancerCanada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
-
Kyoto Breast Cancer Research NetworkPfizerCompletedHormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer FemaleTaiwan, Japan, Korea, Republic of, Australia, Hong Kong
-
National Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerUnited States, Japan
-
Eisai Co., Ltd.CompletedBreast Cancer | HER2-negative Breast CancerJapan
-
Osaka Medical CollegeCompletedBreast Cancer | Effects of Chemotherapy | HER-2 Positive Breast CancerJapan
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Puma Biotechnology, Inc.CompletedHER2+ Metastatic Breast Cancer (MBC)United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
AbbVieRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell CarcinomaUnited States, Israel, Japan, Puerto Rico, Korea, Republic of
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
-
AstraZenecaCompletedHER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 MutationsItaly, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
-
Novartis PharmaceuticalsTerminatedOvarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Eli Lilly and CompanyTerminatedHepatocellular Carcinoma | Solid Tumor | Gastric Adenocarcinoma | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Cervical Carcinoma | Triple-negative Breast Cancer | Undifferentiated Pleomorphic Sarcoma | High Grade Serous Ovarian CarcinomaUnited States, Japan
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
National Cancer Center, JapanRecruitingCervical Cancer | Nasopharyngeal Carcinoma | Ovarian Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Clear Cell CarcinomaJapan, Korea, Republic of, Malaysia, Thailand, Philippines, Singapore, Taiwan, Vietnam
-
Novartis PharmaceuticalsCompletedMelanoma | Triple Negative Breast Cancer | Endometrial Carcinoma | Pancreatic CarcinomaUnited States, Germany, Italy, Japan, Belgium, Switzerland, Korea, Republic of, Hong Kong, Finland, France, Spain
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
-
AmgenCompletedBone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast CancerSpain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
-
Bristol-Myers SquibbRecruitingMelanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
-
Novartis PharmaceuticalsRecruitingCarcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States